PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8680797-1 1995 Interferon-alpha (IFN-alpha) exhibits synergistic antitumor activity when combined with tumor necrosis factor-alpha (TNF-alpha) in vitro and in vivo and increases the cytotoxicity of 5-fluorouracil (5-FU) in vitro. Fluorouracil 199-203 tumor necrosis factor Mus musculus 117-126 20463601-0 2010 Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway. Fluorouracil 44-58 tumor necrosis factor Mus musculus 125-152 20463601-7 2010 MC38 cells pretreated with 5-FU exhibited enhanced expression of procaspase 8 and efficiently underwent apoptosis by TNF-alpha with activation of caspase 8. Fluorouracil 27-31 tumor necrosis factor Mus musculus 117-126 20463601-9 2010 These results indicate that combined therapy with a DC vaccine and 5-FU is a promising strategy for cancer treatment mediated by the tumoricidal activity of NK cells through the TNF-alpha pathway. Fluorouracil 67-71 tumor necrosis factor Mus musculus 178-187 16538045-4 2006 On the other hand, 5-FU 20 mg/kg also caused a significant decline in the amount of produced TNF-alpha but it showed no apparent effects on the number of leukocytes and the body weight. Fluorouracil 19-23 tumor necrosis factor Mus musculus 93-102 16538045-5 2006 These results indicate that LPS-induced TNF-alpha production is a more sensitive measure than leukocyte count used conventionally to detect the immunotoxicity of two anticancer drugs, CDDP and 5-FU, and suggest that it might be a more practical index for hazard identification in clinical treatment with anticancer drugs. Fluorouracil 193-197 tumor necrosis factor Mus musculus 40-49 8680797-2 1995 Using a colon cancer cell line transplanted into nude mice, we examined the effects of pretreatment for 3 days with IFN-alpha (10(6) IU) and/or TNF-alpha (2.9 x 10(3) JRU) on 5-FU metabolism. Fluorouracil 175-179 tumor necrosis factor Mus musculus 144-153 8486533-7 1993 Consequently, the anabolism of 5"-dFUrd to fluoronucleotides and the incorporation of 5-FUra into RNA in colon 26 cells were increased by TNF alpha treatment. Fluorouracil 86-92 tumor necrosis factor Mus musculus 138-147 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). Fluorouracil 77-91 tumor necrosis factor Mus musculus 194-221 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). Fluorouracil 77-91 tumor necrosis factor Mus musculus 223-232 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). Fluorouracil 93-99 tumor necrosis factor Mus musculus 194-221 7759157-1 1995 5"-deoxy-5-fluorouridine (5"-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). Fluorouracil 93-99 tumor necrosis factor Mus musculus 223-232 33927358-7 2021 We demonstrated that co-administration of GA ameliorated 5-FU-induced peripheral muscle fatigue-like behavior via improving muscle quality and mitochondria function, increasing glycogen content and ATP production, reducing lactic acid content and LDH activity, and inhibiting p-AMPK, IL-6 and TNF-alpha expression in skeletal muscle. Fluorouracil 57-61 tumor necrosis factor Mus musculus 293-302 1523983-5 1992 5-FU, CPM and ADM enhanced the antitumor effect when combined with TNF, but CDDP did not. Fluorouracil 0-4 tumor necrosis factor Mus musculus 67-70 2448255-4 1987 Cytotoxic antitumor agents of 5-fluorouracil (5-FU), cyclophosphamide (CY) and bleomycin (BLM) suppressed TNF production in mice primed with CP and challenged with LPS. Fluorouracil 30-44 tumor necrosis factor Mus musculus 106-109 2448255-4 1987 Cytotoxic antitumor agents of 5-fluorouracil (5-FU), cyclophosphamide (CY) and bleomycin (BLM) suppressed TNF production in mice primed with CP and challenged with LPS. Fluorouracil 46-50 tumor necrosis factor Mus musculus 106-109 2448255-5 1987 TNF production suppressed by 5-FU, CY and BLM was partially restored by the combined treatment with OK-432 or PSK. Fluorouracil 29-33 tumor necrosis factor Mus musculus 0-3 3804497-6 1987 The strongest anti-tumor effects in normal BALB/c mice were observed when TNF was combined with the following doses of chemotherapeutic agents: cyclophosphamide 100 mg/kg, adriamycin 5 mg/kg, 5-FU 30-100 mg/kg. Fluorouracil 192-196 tumor necrosis factor Mus musculus 74-77 3804497-10 1987 In this case TNF combinations with cyclophosphamide and 5-FU did not induce tumor regressions. Fluorouracil 56-60 tumor necrosis factor Mus musculus 13-16 31004726-14 2019 Besides, AP could significantly suppressed the 5-FU-mediated increases of the intestinal inflammatory cytokines (TNF-alpha, IFN-gamma, IL-6, IL-1beta and IL-17), while AMO or PGS only inhibited some of them after 5-FU chemotherapy. Fluorouracil 47-51 tumor necrosis factor Mus musculus 113-122 32460371-6 2020 In a xenografted mouse model of cancer, HEP with 5-Fu significantly suppressed tumor growth, inhibited inflammatory markers such as interferon (IFN)-gamma, interleukin (IL)-1beta, IL-2, IL-6, tumor necrosis factor (TNF)-alpha, and lipopolysaccharide (LPS), and regulated the expression of Akt, CCDN1, CKD4, FOXM1, MMP7, MYC, PPAR-alpha, and PPAR-gamma. Fluorouracil 49-53 tumor necrosis factor Mus musculus 192-225 31664952-14 2019 Compared with the control group, mRNA expression of TNF-alpha was significantly up-regulated in the 5-FU group. Fluorouracil 100-104 tumor necrosis factor Mus musculus 52-61 31664952-15 2019 Moreover, mRNA expression of TNF-alpha in the DPP-4i + 5-FU group was down-regulated compared to the 5-FU group. Fluorouracil 55-59 tumor necrosis factor Mus musculus 29-38 31664952-15 2019 Moreover, mRNA expression of TNF-alpha in the DPP-4i + 5-FU group was down-regulated compared to the 5-FU group. Fluorouracil 101-105 tumor necrosis factor Mus musculus 29-38 30342137-4 2019 Additionally, a strength effect was also observed in regulating immune function of GP11 and 5-Fu simultaneous administration, such as enhancing serum interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) secretion, and increasing immune organs weights. Fluorouracil 92-96 tumor necrosis factor Mus musculus 175-202 30207796-0 2019 Serotonin 3 receptor signaling regulates 5-fluorouracil-mediated apoptosis indirectly via TNF-alpha production by enhancing serotonin release from enterochromaffin cells. Fluorouracil 41-55 tumor necrosis factor Mus musculus 90-99 30342137-4 2019 Additionally, a strength effect was also observed in regulating immune function of GP11 and 5-Fu simultaneous administration, such as enhancing serum interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) secretion, and increasing immune organs weights. Fluorouracil 92-96 tumor necrosis factor Mus musculus 204-213 28970092-0 2017 A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFalpha to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil. Fluorouracil 154-168 tumor necrosis factor Mus musculus 72-80 29042284-5 2018 Furthermore, Se-GP11 could enhance the immune functions during the tumor inhibition process of 5-Fu for increasing the cytokines secretion (IL-2 and TNF-alpha) and immune organs weights. Fluorouracil 95-99 tumor necrosis factor Mus musculus 149-158 28970092-5 2017 A targeted therapy for improvement of the therapeutic efficacy of 5-FU and vascular function was performed through administration of TCP-1/TNFalpha fusion protein in this model. Fluorouracil 66-70 tumor necrosis factor Mus musculus 139-147 28374966-8 2017 In cultured colonic epithelial cells, exposure to 5-FU also up-regulated TNF-alpha expression. Fluorouracil 50-54 tumor necrosis factor Mus musculus 73-82 28374966-10 2017 In particular, 5-FU appears to directly induce apoptosis via TNF-alpha and to suppress intestinal cell proliferation, thereby resulting in degradation of the epithelial barrier, as well as in secondary inflammation mediated by inflammatory cytokines. Fluorouracil 15-19 tumor necrosis factor Mus musculus 61-70 28428709-9 2017 5-FU-induced expression of IL-13, IL-17A, TNF-alpha, and IFN-gamma in the ileum was Fn14 dependent. Fluorouracil 0-4 tumor necrosis factor Mus musculus 42-51 27739418-7 2016 Then, we detected the effect of anti-TNF-alpha treatment and it synergistic function with 5-FU in an HCC xenograft mouse model and in HCC cell lines. Fluorouracil 90-94 tumor necrosis factor Mus musculus 37-46 28127258-10 2017 RESULTS: TNF-alpha strengthened the cytotoxicity of docetaxel, 5-FU and cisplatin against breast cancer cells both in vitro and in vivo. Fluorouracil 63-67 tumor necrosis factor Mus musculus 9-18 26847386-7 2016 Tumor necrosis factor-alpha, interleukin-1beta and interferon gamma mRNA expression levels were significantly downregulated in the colon tissue of DSS mice treated with 5-FU compared with the untreated DSS mice (P<0.05). Fluorouracil 169-173 tumor necrosis factor Mus musculus 0-27 26003042-5 2015 In the combined therapy, the antitumor action of 5-fluorouracil (5-FU) was potentiated when the mice were pretreated with a low dose of TNFalpha (1ng/mouse) and to a greater extent by the same concentration of TCP-1/TNFalpha. Fluorouracil 49-63 tumor necrosis factor Mus musculus 136-144 26406888-10 2015 Those mice in 5-FU groups had significantly higher proinflammatory cytokine levels (TNF-alpha: 234.80 vs. 29.10, P<0.001, IL-6: 25.13 vs. 7.43, P<0.001, IFN-gamma: 22.07 vs. 17.06, P = 0.137). Fluorouracil 14-18 tumor necrosis factor Mus musculus 84-93 26406888-12 2015 We also found TNF-alpha, IL-1beta and IL-6 mRNA expressions were up-regulated in intestinal mucositis tissues following 5-FU treatment (TNF-alpha: 4.35 vs. 1.18, IL-1beta: 2.29 vs. 1.07, IL-6: 1.49 vs. 1.02) and that probiotics treatment suppressed this up-regulation (P<0.05). Fluorouracil 120-124 tumor necrosis factor Mus musculus 14-23 26406888-12 2015 We also found TNF-alpha, IL-1beta and IL-6 mRNA expressions were up-regulated in intestinal mucositis tissues following 5-FU treatment (TNF-alpha: 4.35 vs. 1.18, IL-1beta: 2.29 vs. 1.07, IL-6: 1.49 vs. 1.02) and that probiotics treatment suppressed this up-regulation (P<0.05). Fluorouracil 120-124 tumor necrosis factor Mus musculus 136-148 26003042-5 2015 In the combined therapy, the antitumor action of 5-fluorouracil (5-FU) was potentiated when the mice were pretreated with a low dose of TNFalpha (1ng/mouse) and to a greater extent by the same concentration of TCP-1/TNFalpha. Fluorouracil 49-63 tumor necrosis factor Mus musculus 216-224 26003042-5 2015 In the combined therapy, the antitumor action of 5-fluorouracil (5-FU) was potentiated when the mice were pretreated with a low dose of TNFalpha (1ng/mouse) and to a greater extent by the same concentration of TCP-1/TNFalpha. Fluorouracil 65-69 tumor necrosis factor Mus musculus 136-144 26003042-5 2015 In the combined therapy, the antitumor action of 5-fluorouracil (5-FU) was potentiated when the mice were pretreated with a low dose of TNFalpha (1ng/mouse) and to a greater extent by the same concentration of TCP-1/TNFalpha. Fluorouracil 65-69 tumor necrosis factor Mus musculus 216-224 26003042-8 2015 At the same time, TCP-1/TNFalpha significantly improved 5-FU absorption into the tumor mass. Fluorouracil 56-60 tumor necrosis factor Mus musculus 24-32 25861418-11 2015 Radioimmunoassay showed that mice treated with AHCC plus 5-FU had the highest serum levels of IL-2 and TNFalpha compared with the vehicle group and 5-FU group. Fluorouracil 57-61 tumor necrosis factor Mus musculus 103-111 22791308-12 2013 Mice receiving FYG alone or FYG plus 5-FU had higher serum levels of TNF-a (P <0.01) compared with the vehicle. Fluorouracil 37-41 tumor necrosis factor Mus musculus 69-74 25337561-12 2013 The expression of Nuclear factor-kappa B p65 (NF-kappaB p65) protein and TNF-alpha mRNA were significantly higher in 5-FU treated group compared to those of control group. Fluorouracil 117-121 tumor necrosis factor Mus musculus 73-82 24992758-8 2014 Serum levels of TNF-alpha, IL-2, and IFN-gamma, frequencies of CD4 + and CD8+ T cells in the spleen, and splenic NK and CTL activities were also significantly increased in mice treated with 5-FU+PL or 5-FU+PTM compared with mice treated with 5-FU alone (P < 0.05). Fluorouracil 190-194 tumor necrosis factor Mus musculus 16-25 24189396-4 2014 Moreover, a increased effect was also observed in boosting immunity functions when the Heps-bearing mice receiving SCPP11 combination with 5-Fu administration, including increased in thymus indexes and enhancing serum IL-2 and TNF-alpha secretion. Fluorouracil 139-143 tumor necrosis factor Mus musculus 227-236 23072534-10 2013 The up-regulation of TNF-alpha, IL-1beta and IL-6 following 5-FU treatment was also attenuated by ramosetron. Fluorouracil 60-64 tumor necrosis factor Mus musculus 21-30 22403796-7 2012 Furthermore, the 5-FU-mediated upregulation of TNF-alpha, IL-1beta, and NOX1 and the production of reactive oxygen species were significantly attenuated in Nox1KO mice compared with that in WT mice. Fluorouracil 17-21 tumor necrosis factor Mus musculus 47-56 22648862-7 2012 Mice from the 5FU (5-Fluorouracil) group presented weight loss, ulcerations and inflammatory infiltration of neutrophils and eosinophils, increased expression of IL6 and TNF-alpha and increased intestinal permeability. Fluorouracil 20-34 tumor necrosis factor Mus musculus 171-180 23107827-9 2013 5-FU-induced epithelial damage increased the MPO activity (neutrophil number) and the level of pro-inflammatory cytokines (IL-4, TNF-alpha, IL-1beta and CXCL-8) in the duodenum. Fluorouracil 0-4 tumor necrosis factor Mus musculus 129-138 23382968-3 2013 In the present study, the expressions of mRNAs that encode inflammatory cytokines, TNF-alpha, IL-1beta, IL-6, Il-17A and IL-22, were significantly increased throughout the entire colon of mice that exhibited diarrhea following 5-FU administration. Fluorouracil 227-231 tumor necrosis factor Mus musculus 83-92 21153821-9 2011 RESULTS: 5-FU treatment decreased the duodenal villus height/crypt depth ratio, increased MPO activity, and increased the concentration of TNF-alpha, IL-1beta and KC in comparison with saline-treated animals. Fluorouracil 9-13 tumor necrosis factor Mus musculus 139-148